
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **MARCHF1**: Involved in protein ubiquitination, potentially regulating immune responses.<br>- **GPX1**: Encodes glutathione peroxidase, involved in detoxifying hydrogen peroxide, indicating oxidative stress response.<br>- **TYROBP**: An adaptor protein involved in immune cell signaling, particularly in myeloid cells.<br>- **SPI1 (PU.1)**: A transcription factor critical for myeloid and lymphoid lineage development.<br>- **CSF1R**: A receptor for colony-stimulating factor 1, important for macrophage differentiation and survival.<br>- **CYBB**: Encodes a component of the NADPH oxidase complex, involved in reactive oxygen species production in phagocytes.<br>- **FPR3**: A receptor involved in chemotaxis of immune cells.<br>- **LYZ**: Encodes lysozyme, an enzyme with antibacterial properties, often expressed in myeloid cells.<br><br>### Step 2: List the Key Cell Type Markers<br>- **CD74, HLA-DPA1, HLA-DRB5, HLA-DRB1, HLA-DRA, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DMB**: These are MHC class II molecules and associated proteins, indicating antigen-presenting cells, such as macrophages or dendritic cells.<br>- **C1QC, C1QB, C1QA**: Components of the complement system, typically expressed in macrophages.<br>- **CD68**: A marker for macrophages and monocytes.<br>- **FCER1G, FCGR3A, FCGR2A**: Fc receptors, often found on macrophages and other immune cells.<br>- **AIF1 (IBA1)**: A marker for microglia and macrophages.<br>- **MS4A6A**: Associated with immune cells, particularly macrophages.<br>- **LILRB4**: An inhibitory receptor found on myeloid cells.<br>- **CD14**: A co-receptor for the detection of bacterial lipopolysaccharide, expressed on monocytes and macrophages.<br>- **ITGB2**: Integrin beta-2, involved in leukocyte adhesion and signaling.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as CellMarker, PanglaoDB, and the Human Protein Atlas, these markers are predominantly associated with myeloid lineage cells, particularly macrophages and monocytes. The presence of MHC class II molecules and complement components strongly suggests antigen-presenting capabilities.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of these markers, the most likely general cell type is **macrophages**. The combination of MHC class II molecules, complement components, and macrophage-specific markers like CD68 and CD14 supports this conclusion.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Tumor-associated macrophages (TAMs)**: Given the breast cancer tissue context, TAMs are highly probable. They often express MHC class II molecules and are involved in tumor microenvironment modulation.<br>2. **Classical (M1) macrophages**: Characterized by high expression of MHC class II and pro-inflammatory markers, they are involved in antigen presentation and immune response.<br>3. **Non-classical (M2) macrophages**: Typically involved in tissue repair and anti-inflammatory responses, they may also express some of the markers listed, albeit usually with a different profile.<br><br>The most likely subtype, considering the tumor context and marker expression, is **tumor-associated macrophages (TAMs)**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The ranked marker list from the breast cancer tissue dataset predominantly indicates a macrophage cell type, with strong evidence pointing towards tumor-associated macrophages (TAMs). This is supported by the expression of MHC class II molecules, complement components, and macrophage-specific markers. The presence of these markers aligns with the known roles of TAMs in the tumor microenvironment, including immune modulation and interaction with cancer cells.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**: <br>   - The markers used in the annotation are present in the provided marker list. <br>   - The markers such as CD68, CD14, and MHC class II molecules (e.g., HLA-DPA1, HLA-DRB1) are well-known markers for macrophages, particularly tumor-associated macrophages (TAMs) in the context of breast cancer tissue.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The analysis does not strongly suggest the presence of multiple distinct cell types. The markers predominantly indicate a macrophage lineage, specifically tumor-associated macrophages (TAMs), which is appropriate given the breast cancer tissue context.<br><br>The annotation aligns well with the known roles and marker expressions of TAMs in the tumor microenvironment, supporting the conclusion drawn in the analysis.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">macrophages</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>tumor-associated macrophages (TAMs)</li><li>classical (M1) macrophages</li><li>non-classical (M2) macrophages</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the marker list and its implications for cell type identification within the context of breast cancer tissue. The analysis correctly identifies macrophages, specifically tumor-associated macrophages (TAMs), as the primary cell type, which is consistent with the expression of key markers such as CD68, CD14, and various MHC class II molecules. These markers are well-known indicators of macrophage lineage and are particularly relevant in the tumor microenvironment.<br><br>The annotation process shows a balanced consideration of multiple markers, rather than over-focusing on a single one. For instance, the inclusion of markers like TYROBP, SPI1, and CSF1R, which are involved in immune cell signaling and macrophage differentiation, supports the identification of macrophages. The analysis also appropriately considers the rank and importance of markers, as evidenced by the emphasis on MARCHF1 and GPX1, which appear early in the list and are relevant to immune responses and oxidative stress.<br><br>The annotation provides a comprehensive view of the cell types present, identifying not only the main cell type (macrophages) but also potential subtypes (TAMs, classical M1, and non-classical M2 macrophages). This reflects an understanding of the complexity and heterogeneity of macrophage populations in the tumor microenvironment.<br><br>However, there are some areas for improvement. While the analysis correctly identifies macrophages as the predominant cell type, it could have explored the possibility of other immune cell types that might be present, given the diverse marker list. Additionally, the analysis could have provided more detail on the functional implications of the identified subtypes, particularly in the context of breast cancer.<br><br>Overall, the annotation is scientifically accurate, well-balanced in its use of markers, and captures the general picture of the cell populations present in the dataset. There are no obvious misclassifications or oversights, and the analysis is consistent with the known roles of the identified markers.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    